Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Årdal

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Bulletin of the World Health Organization|January 9, 2025
Fragmented markets for older antibiotics and child formulations, Denmark, Norway, SwedenChristine Årdal, Mohamed Gawad, Enrico Baraldi, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|August 28, 2018
Should Antibiotics Be Controlled Medicines? Lessons from the Controlled Drug RegimenLive Storehagen, Friha Aftab, Christine Årdal, et al.
Bulletin of the World Health Organization|March 3, 2017
An antibiotic's journey from marketing authorization to use, NorwayChristine Årdal, Hege Salvesen Blix, Jens Plahte, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 13, 2024
The multifaceted nature of lack of access to antibiotics: types of shortage and specific causes, consequences, and solutionsEnrico Baraldi, Christine Årdal, Emil Aho, et al.
Journal of Pharmaceutical Policy and Practice|November 2, 2016
An assessment of the future impact of alternative technologies on antibiotics marketsEjike Nwokoro, Ross Leach, Christine Årdal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial ResistanceChristine Årdal, John-Arne Røttingen, Aleksandra Opalska, et al.
Jac-Antimicrobial Resistance|July 5, 2021
A case study on <i>Staphylococcus aureus</i> bacteraemia: available treatment options, antibiotic R&D and responsible antibiotic-use strategiesAnnelie A Monnier, Evelina Tacconelli, Christine Årdal, et al.
BMJ Open|March 5, 2024
Availability of essential, generic medicines before and during COVID-19 at selected public pharmaceutical supply agencies in Ethiopia: a comparative cross-sectional studyTsegaye Melaku, Zeleke Mekonnen, Gudina Terefe Tucho, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2021
Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020Kevin Outterson, Ebiowei S F Orubu, John Rex, et al.
BMC Health Services Research|May 20, 2023
The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods studyZeleke Mekonnen, Tsegaye Melaku, Gudina Terefe Tucho, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Bulletin of the World Health Organization|January 9, 2025
Fragmented markets for older antibiotics and child formulations, Denmark, Norway, SwedenChristine Årdal, Mohamed Gawad, Enrico Baraldi, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|August 28, 2018
Should Antibiotics Be Controlled Medicines? Lessons from the Controlled Drug RegimenLive Storehagen, Friha Aftab, Christine Årdal, et al.
Bulletin of the World Health Organization|March 3, 2017
An antibiotic's journey from marketing authorization to use, NorwayChristine Årdal, Hege Salvesen Blix, Jens Plahte, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 13, 2024
The multifaceted nature of lack of access to antibiotics: types of shortage and specific causes, consequences, and solutionsEnrico Baraldi, Christine Årdal, Emil Aho, et al.
Journal of Pharmaceutical Policy and Practice|November 2, 2016
An assessment of the future impact of alternative technologies on antibiotics marketsEjike Nwokoro, Ross Leach, Christine Årdal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial ResistanceChristine Årdal, John-Arne Røttingen, Aleksandra Opalska, et al.
Jac-Antimicrobial Resistance|July 5, 2021
A case study on <i>Staphylococcus aureus</i> bacteraemia: available treatment options, antibiotic R&D and responsible antibiotic-use strategiesAnnelie A Monnier, Evelina Tacconelli, Christine Årdal, et al.
BMJ Open|March 5, 2024
Availability of essential, generic medicines before and during COVID-19 at selected public pharmaceutical supply agencies in Ethiopia: a comparative cross-sectional studyTsegaye Melaku, Zeleke Mekonnen, Gudina Terefe Tucho, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2021
Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020Kevin Outterson, Ebiowei S F Orubu, John Rex, et al.
BMC Health Services Research|May 20, 2023
The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods studyZeleke Mekonnen, Tsegaye Melaku, Gudina Terefe Tucho, et al.
Pageof 4